文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

挽救性低剂量率近距离放疗治疗根治性放疗后局部复发前列腺癌

Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-06-22

该回顾性单中心分析纳入2006至2021年94例接受挽救性I-125低剂量率近距离放疗的局部复发前列腺癌患者,中位随访34个月,2年无失败生存率82%、3年66%,晚期3级泌尿和直肠毒性分别为12%和1%,三种植入体积组间毒性和疗效无显著差异。

要点

  • 挽救性低剂量率近距离放疗后2年无失败生存率82%、3年66%。
  • 晚期3级泌尿毒性和直肠毒性分别见于12%和1%的患者。
  • 三种植入体积组间毒性和疗效无显著差异。

核心结论

  • 挽救性近距离放疗的疗效和毒性结果与MASTER荟萃分析中低剂量率组一致,证实其为局部复发前列腺癌有效且安全的选择。
  • 作者认为聚焦治疗可能有助于减少晚期严重毒性,尤其是泌尿毒性。

研究设计与样本

  • 回顾性单中心分析,在综合癌症中心开展,纳入2006至2021年接受挽救性I-125低剂量率近距离放疗的94例局部复发前列腺癌患者。
  • 靶区为全腺体±GTV加量、半腺体或仅GTV,处方剂量90至145 Gy,毒性按CTCAE v5.0分级。

主要发现

  • 中位随访34个月,无失败生存率2年为82%、3年为66%。
  • 初次放疗为外照射者73例(78%),中位剂量76 Gy;为I-125近距离放疗者21例(22%),处方剂量145 Gy。
  • 挽救时中位PSA为3.75 ng/ml,首次与挽救放疗中位间隔9.4年;32%的患者联合雄激素剥夺治疗,仅4%为去势抵抗。
  • 多因素分析中仅复发时激素敏感性和欧洲泌尿外科学会(EAU)预后分组与无失败生存率相关。
  • 晚期3级泌尿毒性和直肠毒性分别见于12%和1%的患者,三种植入体积组间毒性和疗效无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal management of locally recurrent prostate cancer after definitive irradiation is still unclear but local salvage treatments are gaining interest. A retrospective, single-institution analysis of clinical outcomes and treatment-related toxicity after salvage I-125 low-dose-rate (LDR) brachytherapy (BT) for locally-recurrent prostate cancer was conducted in a Comprehensive Cancer Center. PATIENTS AND METHODS: A total of 94 patients treated with salvage LDR-BT between 2006 and 2021 were included. The target volume was either the whole-gland +/- a boost on the GTV, the hemigland, or only the GTV. The prescribed dose ranged from 90 to 145 Gy. Toxicity was graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. RESULTS: Median follow-up was 34 months. Initial radiotherapy was external beam radiotherapy in 73 patients (78 %) with a median dose of 76 Gy and I-125 BT in 21 patients (22 %) with a prescribed dose of 145 Gy. Median PSA at salvage was 3.75 ng/ml with a median interval between first and salvage irradiation of 9.4 years. Salvage brachytherapy was associated with androgen deprivation therapy for 32 % of the patients. Only 4 % of the patients were castrate-resistant. Failure free survival was 82 % at 2 years and 66 % at 3 years. The only factors associated with failure-free survival on multivariate analysis were hormonosensitivity at relapse and European Association of Urology (EAU) prognostic group. Late grade 3 urinary and rectal toxicities occurred in 12 % and 1 % of the patients respectively.No significant difference in toxicity or efficacy was observed between the three implant volume groups. CONCLUSION: The efficacy and toxicity results are consistent with those in the LDR group of the MASTER meta-analysis. Salvage BT confirms to be an effective and safe option for locally recurrent prostate cancer. A focal approach could be interesting to reduce late severe toxicities, especially urinary.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Meraouna Y, Blanchard P, Losa S, et al. Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation. Clin Transl Radiat Oncol. 2024. PMID: 39027689. doi:10.1016/j.ctro.2024.100809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。